Pricing Log in Create free account
Friday 6 November 2026 Export ELAN’s income statement to Excel — free account

Elanco Animal Health Incorporated

ELAN Healthcare Drug Manufacturers Specialty & Generic

Elanco Animal Health Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 6.22% from fiscal 2024.

Revenue
+10.2%
EPS
+450.0%
Free cash flow
+35.6%
Total debt
−6.91%

Quarter to June 2026, against a year earlier

23.74 1.57 −6.20%
Market cap
$11.8B
P/E
0.0×
Fwd P/E
161×
Dividend yield
—
F-score
5/9
Altman Z
1.28
Beneish M
−2.68
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Elanco Animal Health Incorporated (ELAN) SEC filings, changes and red flags

Red flags

No red flags have been raised by Elanco Animal Health Incorporated’s filings on file.

Filings

Form Period Filed What it reports Flags
8-K Nov 6, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2026 P1I2: 4 added · 28 modified
P2I1A: no material changes, the filing says
8-K Aug 5, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K May 21, 2026 5.07 Submission of matters to a vote of security holders
10-Q Mar 31, 2026
8-K May 6, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Dec 31, 2025 1: 16 added · 17 removed · 56 modified
1A: 4 added · 14 removed · 85 modified
7: 25 added · 20 removed · 37 modified
8-K Feb 24, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 12, 2026 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Dec 5, 2025 2.05 Costs of exit or disposal activities; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Sep 30, 2025
8-K Nov 5, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Oct 31, 2025 1.01 Entry into a material definitive agreement; 2.03 Creation of a direct financial obligation; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
8-K Aug 7, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Mar 31, 2025
8-K May 7, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Dec 31, 2024
8-K Feb 25, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Sep 30, 2024
8-K Nov 7, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2024
8-K Aug 8, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K May 8, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 22, 2024 2.02 Results of operations and financial condition; 2.05 Costs of exit or disposal activities; 9.01 Financial statements and exhibits
8-K Nov 7, 2023 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.